Statistical subgroup analysis
| Telomere fluorescence in kMESF . | N . | p . | Estimated mean . | SE . | Range . | Estimated mean shift from normal . | SE . | P Value . |
|---|---|---|---|---|---|---|---|---|
| PBLs of patients with CML | ||||||||
| total | 123 | 59 | 11.0 | 0.3 | 5.0-25.4 | −2.1 | 0.3 | P < .001 |
| in CP | 96 | 53 | 11.3 | 0.4 | 4.4-25.4 | −1.9 | 0.4 | P < .001 |
| in AP/BC | 15 | 12 | 9.5 | 0.7 | 5.1-13.9 | −4.1 | 0.8 | P < .001 |
| in CR | 12 | 8 | 11.4 | 0.6 | 7.9-15.7 | −1.8 | 0.5 | P = .016 |
| All clinical stages | ||||||||
| PBLs vs | 51 | 42 | 10.3 | 0.4 | 5.4-17.1 | P < .001 | ||
| Ph− T lymphocytes | 51 | 42 | 15.0 | 0.4 | 8.0-20.7 | |||
| CP samples with | ||||||||
| rdCP <2 y vs | 27 | 15 | 10.9 | 0.8 | 5.1-21.1 | P = .046 | ||
| rdCP ≥2 y | 49 | 11 | 12.6 | 0.5 | 5.9-25.4 | |||
| Samples with | ||||||||
| Ph+LTC-ICs* vs | 15 | 12 | 11.2 | 1.1 | ||||
| Ph−LTC-ICs | 16 | 11 | 12.6 | 1.0 |
| Telomere fluorescence in kMESF . | N . | p . | Estimated mean . | SE . | Range . | Estimated mean shift from normal . | SE . | P Value . |
|---|---|---|---|---|---|---|---|---|
| PBLs of patients with CML | ||||||||
| total | 123 | 59 | 11.0 | 0.3 | 5.0-25.4 | −2.1 | 0.3 | P < .001 |
| in CP | 96 | 53 | 11.3 | 0.4 | 4.4-25.4 | −1.9 | 0.4 | P < .001 |
| in AP/BC | 15 | 12 | 9.5 | 0.7 | 5.1-13.9 | −4.1 | 0.8 | P < .001 |
| in CR | 12 | 8 | 11.4 | 0.6 | 7.9-15.7 | −1.8 | 0.5 | P = .016 |
| All clinical stages | ||||||||
| PBLs vs | 51 | 42 | 10.3 | 0.4 | 5.4-17.1 | P < .001 | ||
| Ph− T lymphocytes | 51 | 42 | 15.0 | 0.4 | 8.0-20.7 | |||
| CP samples with | ||||||||
| rdCP <2 y vs | 27 | 15 | 10.9 | 0.8 | 5.1-21.1 | P = .046 | ||
| rdCP ≥2 y | 49 | 11 | 12.6 | 0.5 | 5.9-25.4 | |||
| Samples with | ||||||||
| Ph+LTC-ICs* vs | 15 | 12 | 11.2 | 1.1 | ||||
| Ph−LTC-ICs | 16 | 11 | 12.6 | 1.0 |
Samples with Ph+ LTC-IC were defined as those in which ≥4 colonies from the LTC-IC assays were analyzed cytogenetically of which ≥50% were Ph+. All remaining samples analyzed were considered Ph−.
AP/BC indicates accelerated phase/blast phase; CML, chronic myeloid leukemia; CP, chronic phase; CR, cytogenic remission; LTC-IC, long-term culture-initiating assays; kMESF, kilo molecular equivalents of soluble fluorochrome units; N, number of samples analyzed in each group; p, number of patients; PBL, peripheral blood leukocytes; rdCP, remaining duration of CP; comparison of mixed populations of cross-sectional and sequential samples was performed as indicated in “Materials and methods.”